Are NAD+ injections FDA-approved? Status, evidence and risks
As of October 15, 2026, there is no FDA-approved NAD+ drug; NAD (nicotinamide adenine dinucleotide) sits in Category 1 of FDA's interim 503A policy, which means FDA does not intend to act against licensed pharmacies that compound it while the agency evaluates it. That is enforcement discretion, not approval, and it says nothing about whether NAD+ works. Human evidence for NAD+ injections or IV drips comes from small, short studies; most ageing claims rest on animal research. Athletes should know that WADA prohibits IV infusions over 100 mL per 12 hours outside hospital care.
Status at a glance
| Check | Status as of October 15, 2026 | Source · read date |
|---|---|---|
| FDA approval | No FDA-approved NAD+ drug product found. | FDA · read October 15, 2026 |
| 503A interim category | Category 1: “Nicotinamide Adenine Dinucleotide (NAD)” and the reduced form NADH (categories PDF updated May 14, 2026). A separate entry, “Beta-Nicotinamide Adenine Dinucleotide”, appears in Category 3. | FDA · read October 15, 2026; FDA 503A page |
| FDA advisory committee (PCAC) | None found for 2025–2026. | FDA · read October 15, 2026 |
| WADA 2026 Prohibited List | NAD+ is not named. Method M2.2 prohibits IV infusions or injections over 100 mL per 12 hours outside hospital care, which can apply to NAD+ drips. | World Anti-Doping Agency · read October 15, 2026 |
| FDA warning letters, 2026 | None found naming NAD+. | FDA warning letters · read October 15, 2026 |
| WADA 2027 list | Not named on the 2027 list (in force January 1, 2027); the M2.2 limit on IV infusions over 100 mL per 12 hours is unchanged. | World Anti-Doping Agency · read October 15, 2026 |
What Category 1 means, and what it does not
FDA describes Category 1 substances this way: “These substances may be eligible for inclusion on the 503A bulks list” (FDA). While FDA evaluates them, it does not intend to take action against licensed 503A pharmacies that compound with them under the other conditions of the law. That is enforcement discretion. It is not approval, it is not a finding that NAD+ works, and it can change.
Note the naming detail: FDA lists “Nicotinamide Adenine Dinucleotide (NAD)” in Category 1 but “Beta-Nicotinamide Adenine Dinucleotide” in Category 3, where nominations lacked enough information for FDA to evaluate. Ask the pharmacy which nominated substance it uses.
Human evidence
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell. Human studies of NAD+ injections, IV drips and oral precursors have been small and short. They can show that blood NAD+ levels rise; they have not shown that NAD+ therapy slows ageing, restores energy or improves thinking. We have not re-read that literature for this update and do not cite individual trials. See NAD+ evidence.
Animal and laboratory evidence
Most of the striking ageing claims come from studies in mice and cell cultures. Mouse longevity findings have often failed to carry over to people, so we keep them separate and do not present them as human results.
Risks
NAD+ is usually given by IV drip or injection, so the main practical risks are those of any compounded sterile preparation and of IV access itself: sterility, correct concentration and a setting able to handle a reaction. Long-term safety of repeated high doses has not been established in trials. For athletes, a drip over 100 mL in 12 hours outside hospital care breaches WADA method M2.2 regardless of what is in the bag. See NAD+ safety.
Legal sourcing: who can supply it
Because NAD is in Category 1, a licensed clinician may prescribe it and a licensed 503A pharmacy may compound it under FDA’s interim policy. That is the route to insist on. A clinic or IV lounge should name the pharmacy that compounds its NAD+. See how to verify a provider.
The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.
October 2026: what changed
- April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
- July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
- October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.
For NAD+: its Category 1 status did not change in 2026, and it was not on the July PCAC agenda. The interim access policy concerns “certain peptides”; NAD+ is not a peptide, and nothing reported so far suggests a change for it. For prices, see NAD+ therapy cost; we have not verified any.
Frequently asked questions
Are NAD+ injections FDA-approved?
As of October 15, 2026, there is no FDA-approved NAD+ drug; NAD (nicotinamide adenine dinucleotide) sits in Category 1 of FDA's interim 503A policy, which means FDA does not intend to act against licensed pharmacies that compound it while the agency evaluates it. That is enforcement discretion, not approval, and it says nothing about whether NAD+ works. Human evidence for NAD+ injections or IV drips comes from small, short studies; most ageing claims rest on animal research. Athletes should know that WADA prohibits IV infusions over 100 mL per 12 hours outside hospital care.
What does FDA Category 1 mean for NAD+?
FDA says Category 1 substances “may be eligible for inclusion on the 503A bulks list.” While it evaluates them, FDA does not intend to act against licensed 503A pharmacies that compound them. It is temporary enforcement discretion, not approval or proof of benefit.
Do NAD+ IV drips break anti-doping rules?
They can. NAD+ itself is not named on WADA’s 2026 list, but method M2.2 prohibits IV infusions or injections of more than 100 mL in a 12-hour period, except during hospital treatment, surgery or clinical investigations. Many IV drips exceed that volume.
Is there good human evidence for NAD+ therapy?
Not for the outcomes it is sold for. Human studies are small and short and mostly show that NAD+ levels rise. Claims about slower ageing come largely from animal research, which often fails to translate to people.
Is NAD+ a peptide?
No. NAD+ is a coenzyme, a small molecule rather than a chain of amino acids. It is sold through the same longevity clinics as peptides, which is why we cover it, but the peptide-specific interim policy reported in October 2026 is not about NAD+.
New this month: what is known about FDA’s peptide interim access policy · a status table for 16 peptides (FDA and WADA).
Sources
- FDA — Interim policy categories for 503A and 503B bulk drug substances (PDF, updated May 14, 2026) (read October 15, 2026)
- FDA — Bulk drug substances used in compounding under section 503A (page current as of May 14, 2026) (read October 15, 2026)
- World Anti-Doping Agency — Prohibited List (2026 list in force) (read October 15, 2026)
- World Anti-Doping Agency — 2026 Prohibited List (PDF) (read October 15, 2026)
- OIRA (reginfo.gov) — Interim Access Policy for Compounding Using Certain Peptides, RIN 0910-ZD94 (pending EO 12866 review) (read October 15, 2026)
- Reuters via Yahoo News — FDA takes step to change peptide compounding access (October 15, 2026) (read October 15, 2026)
- World Anti-Doping Agency — 2027 Prohibited List (published September 21, 2026; in force January 1, 2027) (read October 15, 2026)